# Cancer Biological Therapy Market

> EMEA Cancer Biological Therapy Market information, by type (monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others) by end users (hospitals & clinics, cancer research centers, laboratories) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.67%
- **2024:** $ 116.29 Billion
- **2025:** $ 130.03 Billion
- **2035:** $ 356.19 Billion
- **Key Players:** Roche (CH), Bristol-Myers Squibb (US), Amgen (US), Merck & Co. (US), Novartis (CH), Gilead Sciences (US), AstraZeneca (GB), Pfizer (US), Johnson & Johnson (US)

**Report ID:** MRFR/Pharma/0173-CR · **Pages:** 85 · **Author:** Rahul Gotadki · **Last Updated:** January 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/cancer-biological-therapy-market-616

---

## Market Summary

## **Europe, the Middle East, and Africa Cancer Biological Therapy Market Overview**

The Cancer Biological Therapy Market Size was valued at USD 10.70 Billion in 2023. The Global Cancer Biological Therapy industry is projected to grow from USD 11.00 Billion in 2024 to USD 14.50 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.22% during the forecast period (2024 - 2032).Cancer is ranked the world’s second most lethal disease caused due to abnormal cell growth that spreads across the human body.

Most of the vital and visible signs of cancer are hair loss, weight loss, bleeding in internal organs, benign tumors, lumps in the body, and changes in digestion, and improper bowel movement. There are more than 100 types of cancer known to humans. Major causes of cancer in humans are excessive use of tobacco, no or minimal physical activity, high sugar intake, excessive smoking and drinking, high junk food intake, and other infections like hepatitis B and C.

Most individuals inherit cancer is caused because of mutation of genes. Stage and type of cancer are the deciding factors if the patient could survive the illness or not. Proper screening, ration therapy, chemotherapy, surgery, and maintaining a proper lifestyle are the only start of cancer treatment. Progressive screening and treatment and clearer PET scans give a cancer patient an ideal life survival up to 10 years of the first sign of cancer. The overall health of the patient is degraded to a greater extent.

Many healthcare centers have invested in cancer clinics and hospitals to develop hypotheses and models to have a better understanding of the disease. It is reported by WHO that more than 18 million new cancer cases are registered annually with an investment of more than 1.6 trillion US dollars per year.

**COVID-19 Analysis:**

The global prevalence of COVID-19 since the November of 2019 has held down the world economically, socially, and politically. The world suffered major losses in terms of manpower, local business, corporates, etc. The countries around the globe went into complete lockdown to contain the virus in local areas. Travel and communication were completely restricted due to the fear of the virus and the effect and cure unknown to mankind. People suffering from cancer had adverse effects and, in few cases, it led to life loss.

The government, charity, and private funds which were the source of cancer research were depleted due to loss in business and limited money to globally feed the public during the pandemic. Although the study in cancer research did not come to a stand-still any new venture was not made during the time of the pandemic. Slowly, as the world is coming back on its feet, healthcare centers have seen a rise in public and private investors to aid the study and research of cancer.

## **Europe, the Middle East, and Africa Cancer Biological Therapy Market Dynamics**

**Drivers:**

With more than 18 million new cancer cases are registered annually with an investment of more than 1.6 trillion US dollars per year as recorded in 2016, the EMEA Cancer biological therapy market has seen a high in research and development area in recent years. The healthcare centers around the world have come up with patient assistance programs (PAPs) with the government’s health to create awareness about the type and stages of cancer. With more than 15% of children under cancer, radar has healthcare centers across the world invest more in NICU cancer departments.

There are more than 100 types of cancer known to mankind but few of the major cancers include lung, breast, blood, gastric, colorectal, esophageal, and pancreatic which not only affect the major organs but also decrease the lifespan of humans.

**Opportunities:**

The Europe, the Middle East, and Africa

[cancer biological therapy](../../../reports/cancer-biologic-therapy-market-566)

market is all set to witness growth because of the rising cancer incidences among the geriatric populations on a global level. People who are aged above 50 years are more vulnerable and have high chances of developing cancer cells in the body. The statistics released by the World Cancer Research Fund show that by the beginning of the forecast year of 2018, there were approximately 18 million cases of cancer from different corners of the globe. By the end of the same forecast year, there was a 12.3% growth in the cases, worldwide.

The biological therapies and techniques used help in enhancing the immune system and help in the development of better technologies that are playing a major role in helping people to recover at a fast rate.

**Technology Analysis:**

Cancer biological therapy is rapidly growing due to a greater number of investors interested in funding the research and development department of cancer therapy. Cancer biological therapy deals with injecting drugs in humans on cancer-infected areas to decrease the growth of the tumor or performing radiation-based therapy to the infected areas to diminish the growth.

In certain cancers like breast cancer, lung cancer, gynecologic cancer, etc. infected body parts can also be cut out as it is a proven fact that cancer doesn’t eventually get cured it needs to be treated time again depending on the progression and regular PET scans results. Cancer biological therapy around the world has been studied to analyze the cancer type and factors leading to its growth. This analysis had led the government and private sectors to study the market-growth in cancer study and invest accordingly.

## **Europe, the Middle East, and Africa Cancer Biological Therapy Market Segmentation**

### **EMEA Cancer Biological Therapy Market By Type**

EMEA Cancer biological therapy market is segmented by type as the different type of cancers known to humans like 

[breast cancer](../../../reports/global-breast-cancer-market-1379)

, lungs cancer, blood cancer, prostate cancer, gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, etc. and the different type of therapies used to treat them depending on stage and type like targeted therapy, radiation, cancer growth inhibitors, antibodies, interleukins, vaccines, interferons, colony-stimulating factors and treatments, gene therapy, etc.

### **EMEA Cancer Biological Therapy Market By Vertical**

EMEA Cancer biological therapy market is segmented by vertical as medical centers, clinical trial hospitals, and healthcare centers, laboratories, and cancer-related research and development centers. Few of these centers are funded by the government and the others by private investors depending on the revenue and growth of these centers.

## **EMEA Cancer Biological Therapy Market Regional Analysis**

North America is the current leader of the world’s cancer therapy market due to the high investments done in the research and development center of the cancer department leading to the adaption of cancer therapies. Europe is dominant in the EMEA region of the EMEA Cancer biological therapy market with an expectation of a market rise to more than 20,000 million US dollars by the year 2021. The European EMEA region market of EMEA Cancer biological therapy industry Research forecasts a CAGR of 5.2% by the year 2021.

Asia-Pacific countries like China, Japan, and India have also contributed to the increasing Cancer biological therapy industry and are estimated to continue to grow in upcoming years. Middle East (Oman, Kuwait, UAE, Qatar, Bahrain, and Saudi Arabia) is likely to see a CAGR of 4.3% by 2021 with an estimated revenue of more than 6000 million US dollars.

## **EMEA Cancer biological therapy market Competitive Insights**

The EMEA Cancer biological therapy market is on the global rise due to an alarming rate at which cancer patients are increasing. To be prepared and composed for this increasing number of patients is on the priority of many healthcare departments overall the globe. Public and private sectors have been funded seeing to the expansion of cancer patients and related centers for it. 

**Few of the key market players in the EMEA Cancer biological therapy market are **

**Recent Developments:**

In January 2020, a biopharmaceutical company called ArQule Inc joined hands with Merck and Co. to study the growth and development of a device for kinase inhibitor to treat cancer patients. AVEO Oncology was successful in getting FDA approval and clearance in June 2020, for the discovery and development of a new drug tivozanib for refractory renal [cell disruption](../../../reports/cell-lysis-disruption-market-8358) and carcinoma. Glaxo Smith Kline PLC joined hands with TESARO Inc. in the January of 2019 to pipeline and expand the study of oncology and see if it fits to provide commercial revenue to the EMEA Cancer biological therapy market.

**Report Overview:**

The EMEA Cancer biological therapy market provides a statistical and logical analysis of the market growth and the factors leading to it. The report also addresses the opportunities leading to an increasing EMEA Cancer biological therapy industry by analyzing the supply chain from public and private sectors and the developments made by the R&D department in the cancer region. Globally speaking North America, Europe, China, Japan, and the Middle East are highly invested in the EMEA Cancer biological therapy industryto maintain the growth of the world’s healthcare center.

The report provides a brief insight into the strategic alliances between the public and private sectors for the cancer biological therapy industry.

## Market Drivers

### Rising Incidence of Cancer

The increasing prevalence of cancer worldwide is a primary driver for the Cancer Biological Therapy Market. According to recent statistics, cancer cases are projected to rise significantly, with estimates suggesting that by 2030, there could be over 21 million new cases annually. This alarming trend necessitates the development of effective treatment options, thereby propelling the demand for biological therapies. These therapies, which harness the body's immune system to combat cancer, are becoming increasingly vital as traditional treatments may not suffice for all patients. The Cancer Biological Therapy Market is thus positioned to expand rapidly, as healthcare providers seek innovative solutions to address the growing burden of cancer.

### Growing Awareness and Education

Increasing awareness and education regarding cancer treatment options are pivotal for the Cancer Biological Therapy Market. Patients and healthcare professionals are becoming more informed about the benefits of biological therapies, leading to a shift in treatment preferences. Educational campaigns and initiatives by various organizations have played a significant role in disseminating information about the efficacy and safety of these therapies. As a result, more patients are opting for biological treatments, which are perceived as less invasive and more targeted compared to traditional methods. This heightened awareness is expected to contribute to the expansion of the Cancer Biological Therapy Market, as more individuals seek out these innovative treatment options.

### Regulatory Support and Approvals

Regulatory support and streamlined approval processes are essential drivers for the Cancer Biological Therapy Market. Regulatory agencies are increasingly recognizing the need for expedited pathways for innovative therapies, particularly those that demonstrate significant clinical benefits. For example, the FDA has implemented programs such as Breakthrough Therapy Designation, which facilitates faster development and review of promising treatments. This supportive regulatory environment encourages pharmaceutical companies to invest in the development of biological therapies, knowing that they may receive quicker market access. Consequently, the Cancer Biological Therapy Market is likely to experience accelerated growth as more therapies gain approval and become available to patients.

### Advancements in Research and Development

Ongoing advancements in research and development are crucial for the Cancer Biological Therapy Market. The emergence of novel therapeutic agents, such as monoclonal antibodies and CAR T-cell therapies, has transformed treatment paradigms. Investment in R&D has surged, with funding from both public and private sectors reaching unprecedented levels. For instance, the National Cancer Institute has allocated substantial resources to support innovative research initiatives. These advancements not only enhance the efficacy of treatments but also improve patient outcomes, thereby driving market growth. As new therapies enter the market, the Cancer Biological Therapy Market is likely to witness a surge in adoption rates, reflecting the potential of these cutting-edge solutions.

### Increasing Investment in Healthcare Infrastructure

The growing investment in healthcare infrastructure is a significant driver for the Cancer Biological Therapy Market. Governments and private entities are allocating substantial funds to enhance healthcare facilities, improve access to advanced treatments, and support research initiatives. This investment is particularly evident in emerging markets, where healthcare systems are evolving rapidly. Enhanced infrastructure enables better delivery of biological therapies, ensuring that patients receive timely and effective treatment. As healthcare systems improve, the Cancer Biological Therapy Market is poised for growth, as more patients gain access to innovative therapies that can potentially improve their prognosis.

## Future Outlook

The Cancer Biological Therapy Market is projected to grow at a 10.67% CAGR from 2025 to 2035, driven by advancements in immunotherapy, personalized medicine, and increasing cancer prevalence.

**New opportunities:**

- Development of combination therapies targeting multiple cancer pathways.
- Expansion of telehealth services for remote patient monitoring.
- Investment in AI-driven drug discovery platforms for faster development.

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Monoclonal Antibodies (Largest) vs. Cancer Vaccines (Fastest-Growing)

In the Cancer Biological Therapy Market, Monoclonal Antibodies hold the largest share among all application segments, reflecting their established role in treating various types of cancer. This class of therapies has gained prevalence due to their specificity in targeting cancer cells, leading to improved patient outcomes. Following them, Cancer Vaccines are emerging rapidly, garnering increasing attention for their potential to prevent cancer recurrence and boost immune system response, appealing to both clinical applications and patient interest.

Monoclonal Antibodies (Dominant) vs. Cancer Vaccines (Emerging)

Monoclonal Antibodies represent the dominant force in the Cancer Biological Therapy Market, celebrated for their capability to precisely target cancerous cells while minimizing damage to healthy tissues. Their widespread acceptance is driven by a range of approved products that exemplify successful patient outcomes, thereby solidifying their market position. Conversely, Cancer Vaccines are positioned as an emerging segment, aiming to harness the body's immune system to prevent or combat cancer. Innovations in this area, including personalized vaccines and combination therapies, are fostering rapid growth, pointing to a future where preventive and therapeutic strategies coexist.

### By Type of Cancer: Breast Cancer (Largest) vs. Lung Cancer (Fastest-Growing)

In the Cancer Biological Therapy Market, Breast Cancer dominates the market share, driven by high incidence rates and widespread awareness among healthcare providers and patients. Lung Cancer follows closely, with a significant focus on targeted therapies that cater to the tumor's characteristics. Colorectal and Prostate cancers hold considerable shares as well, with ongoing research and development enhancing their treatment approaches. Leukemia, while having a smaller market share than the others, has specialized therapies that cater to unique patient needs, still contributing to the diversity of the segment.

Breast Cancer: Dominant vs. Lung Cancer: Emerging

Breast Cancer remains the dominant player in the Cancer Biological Therapy Market due to its high prevalence, which has led to significant investments in innovative therapies tailored specifically for it. This segment benefits from strong patient advocacy and government funding for research, facilitating the development of targeted treatments that improve patient outcomes. In contrast, Lung Cancer is emerging, characterized by rapid advancements in immunotherapy and targeted treatment options. The growing incidence of Lung Cancer and increased demand for effective therapies are propelling its growth, making it a focal point for research and development initiatives. The convergence of advanced diagnostics and targeted therapies is likely to enhance treatment efficacy, further bolstering this segment's market position.

### By Treatment Modality: Immunotherapy (Largest) vs. Combination Therapy (Fastest-Growing)

The Cancer Biological Therapy Market is increasingly dominated by immunotherapy, which holds the largest market share among treatment modalities. Targeted therapy remains significant, but immunotherapy's broad applicability across various cancer types sets it apart as a leading choice for treatment. Combination therapy, which merges different therapeutic approaches, is also gaining traction, offering enhanced efficacy and improved patient outcomes, making it a prominent player in the market landscape.

Immunotherapy (Dominant) vs. Combination Therapy (Emerging)

Immunotherapy is recognized as a dominant treatment modality within the Cancer Biological Therapy Market, harnessing the body's immune system to combat cancer more effectively. This approach has demonstrated remarkable success in treating various malignancies, reflecting a shift towards more personalized treatments. In contrast, combination therapy is emerging rapidly, integrating multiple biological mechanisms to optimize treatment responses. This innovative strategy not only aims to overcome resistance but also enhances therapeutic impact. As these modalities evolve, their complementary nature is becoming evident, fostering a trend towards more integrative treatment protocols.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America continues to lead the Cancer Biological Therapy Market, holding a significant 58.14% share as of 2024. The region's growth is driven by advanced healthcare infrastructure, high R&D investments, and a robust regulatory framework that supports innovation. Increasing cancer prevalence and a growing demand for targeted therapies further fuel market expansion. Regulatory bodies are actively promoting the development of novel therapies, enhancing patient access to cutting-edge treatments.

The United States stands out as the primary market, hosting major players like Roche, Bristol-Myers Squibb, and Merck & Co. The competitive landscape is characterized by continuous innovation and strategic collaborations among key companies. The presence of leading pharmaceutical firms ensures a steady pipeline of new therapies, contributing to the region's dominance in the global market. As the market evolves, North America is expected to maintain its leadership position through ongoing advancements in cancer treatment.

### Europe : Emerging Market with Growth Potential

Europe holds a substantial 30.0% share of the Cancer Biological Therapy Market, driven by increasing investments in healthcare and a rising incidence of cancer. The region benefits from a strong regulatory environment that encourages the development of innovative therapies. Initiatives by the European Medicines Agency (EMA) to streamline approval processes for new treatments are expected to further boost market growth. Additionally, the growing emphasis on personalized medicine is shaping demand trends across various countries.

Leading countries such as Germany, France, and the UK are at the forefront of this market, with a competitive landscape featuring key players like Novartis and AstraZeneca. The presence of advanced research institutions and a collaborative approach among stakeholders enhance the region's capacity for innovation. As Europe continues to invest in cancer research and development, it is poised for significant growth in the biological therapy sector.

### Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is witnessing rapid growth in the Cancer Biological Therapy Market, accounting for 22.0% of the global share. This growth is driven by increasing healthcare expenditure, rising cancer incidence, and a growing awareness of advanced treatment options. Governments in countries like China and India are implementing policies to enhance healthcare access and support research initiatives, which are crucial for market expansion. The region's diverse population also presents unique opportunities for tailored therapies.

China and Japan are leading the charge in this market, with significant investments from both local and international pharmaceutical companies. The competitive landscape is evolving, with key players like Amgen and Gilead Sciences making substantial inroads. As the region continues to develop its healthcare infrastructure and regulatory frameworks, it is expected to become a major player in The Cancer Biological Therapy.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region represents a smaller segment of the Cancer Biological Therapy Market, with a share of 6.15%. Despite facing challenges such as limited healthcare infrastructure and regulatory hurdles, the market is gradually expanding due to increasing cancer awareness and rising healthcare investments. Governments are beginning to prioritize cancer treatment, which is expected to drive demand for biological therapies in the coming years. The region's diverse healthcare landscape presents both challenges and opportunities for market players.

Countries like South Africa and the UAE are emerging as key markets, with a growing presence of international pharmaceutical companies. The competitive landscape is characterized by a mix of local and global players, striving to meet the increasing demand for effective cancer treatments. As regulatory frameworks improve and healthcare access expands, the Middle East and Africa are poised for gradual growth in the cancer biological therapy sector.

## Competitive Benchmarking

The Cancer Biological Therapy Market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on personalized medicine. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Merck & Co. (US) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their therapeutic offerings. Roche (CH) emphasizes a strategy centered on precision oncology, aiming to tailor treatments to individual patient profiles, which positions it favorably in a market increasingly oriented towards personalized therapies. Meanwhile, Bristol-Myers Squibb (US) focuses on expanding its immunotherapy portfolio, particularly in combination therapies, which appears to be a critical growth driver in the current landscape. Merck & Co. (US) is also investing heavily in research and development, particularly in the realm of checkpoint inhibitors, which have shown promising results in various cancer types.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. This approach not only enhances operational efficiency but also mitigates risks associated with global supply chain disruptions. The market structure is moderately fragmented, with a mix of established players and emerging biotech firms. The collective influence of these key players shapes competitive dynamics, as they vie for market share through innovative product offerings and strategic collaborations.

In November  Roche (CH) announced a partnership with a leading genomic sequencing company to enhance its capabilities in biomarker discovery. This collaboration is expected to bolster Roche's precision medicine initiatives, allowing for more targeted therapies that align with patient-specific genetic profiles. Such strategic moves are indicative of the company's commitment to maintaining its competitive edge in a rapidly evolving market.

In October  Bristol-Myers Squibb (US) launched a new combination therapy for melanoma, which has shown a 30% improvement in patient outcomes compared to existing treatments. This launch not only reinforces the company's position in the immunotherapy space but also highlights its focus on developing innovative solutions that address unmet medical needs. The strategic importance of this launch lies in its potential to capture significant market share in a highly competitive segment.

In September  Merck & Co. (US) expanded its clinical trial program for its leading checkpoint inhibitor, aiming to explore its efficacy in additional cancer types. This expansion reflects Merck's proactive approach to research and development, as it seeks to solidify its leadership in the immunotherapy market. The strategic implications of this move suggest a long-term commitment to innovation and a desire to stay ahead of competitors in a field that is rapidly advancing.

As of December  current trends in the Cancer Biological Therapy Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing research capabilities and accelerating time-to-market for new therapies. Looking ahead, competitive differentiation is likely to evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of developing robust, sustainable practices that not only meet regulatory standards but also resonate with the growing demand for ethical and responsible healthcare solutions.

## Recent News & Developments

In January 2020, a biopharmaceutical company called ArQule Inc joined hands with Merck and Co. to study the growth and development of a device for kinase inhibitor to treat cancer patients. AVEO Oncology was successful in getting FDA approval and clearance in June 2020, for the discovery and development of a new drug tivozanib for refractory renal [cell disruption](../../../reports/cell-lysis-disruption-market-8358) and carcinoma. Glaxo Smith Kline PLC joined hands with TESARO Inc. in the January of 2019 to pipeline and expand the study of oncology and see if it fits to provide commercial revenue to the EMEA Cancer biological therapy market.

## Report Scope

| MARKET SIZE 2024 | 116.29(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 130.03(USD Billion) |
| MARKET SIZE 2035 | 356.19(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.67% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Bristol-Myers Squibb (US), Amgen (US), Merck & Co. (US), Novartis (CH), Gilead Sciences (US), AstraZeneca (GB), Pfizer (US), Johnson & Johnson (US) |
| Segments Covered | Application, Type of Cancer, End User |
| Key Market Opportunities | Advancements in personalized medicine enhance treatment efficacy in the Cancer Biological Therapy Market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the Cancer Biological Therapy Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Cancer Biological Therapy Market?**
A: As of 2024, the market valuation was 116.29 USD Billion.

**Q: What is the projected market size for the Cancer Biological Therapy Market by 2035?**
A: The market is projected to reach 356.19 USD Billion by 2035.

**Q: What is the expected CAGR for the Cancer Biological Therapy Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 10.67%.

**Q: Which companies are considered key players in the Cancer Biological Therapy Market?**
A: Key players include Roche, Bristol-Myers Squibb, Amgen, Merck & Co., Novartis, Gilead Sciences, AstraZeneca, Pfizer, and Johnson & Johnson.

**Q: What are the main applications of cancer biological therapies?**
A: The main applications include Monoclonal Antibodies, Cancer Vaccines, Cytokines and Interferons, Gene Therapy, and Oncolytic Virus Therapy.

**Q: How does the market for Monoclonal Antibodies compare to other segments?**
A: The market for Monoclonal Antibodies was valued at 40.0 USD Billion in 2024 and is projected to reach 120.0 USD Billion by 2035.

**Q: What types of cancer are primarily targeted by biological therapies?**
A: Biological therapies primarily target Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Leukemia.

**Q: What is the projected market size for Immunotherapy by 2035?**
A: The market for Immunotherapy is expected to grow from 40.0 USD Billion in 2024 to 120.0 USD Billion by 2035.

**Q: What treatment modalities are included in the Cancer Biological Therapy Market?**
A: The treatment modalities include Targeted Therapy, Immunotherapy, Combination Therapy, Adjuvant Therapy, and Neoadjuvant Therapy.

**Q: What is the expected growth trajectory for the Oncolytic Virus Therapy segment?**
A: The Oncolytic Virus Therapy segment was valued at 16.29 USD Billion in 2024 and is projected to reach 56.19 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cancer-biological-therapy-market-616*